- Home
- CET vs JANX Comparison
CET vs JANX Comparison
Compare CET & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- JANX
- Stock Information
- Founded
- CET 1929
- JANX 2017
- Country
- CET United States
- JANX United States
- Employees
- CET N/A
- JANX N/A
- Industry
- CET Finance/Investors Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- CET Finance
- JANX Health Care
- Exchange
- CET Nasdaq
- JANX Nasdaq
- Market Cap
- CET 1.5B
- JANX 1.4B
- IPO Year
- CET N/A
- JANX 2021
- Fundamental
- Price
- CET $51.69
- JANX $28.71
- Analyst Decision
- CET
- JANX Strong Buy
- Analyst Count
- CET 0
- JANX 11
- Target Price
- CET N/A
- JANX $76.55
- AVG Volume (30 Days)
- CET 39.3K
- JANX 1.2M
- Earning Date
- CET 01-01-0001
- JANX 11-06-2025
- Dividend Yield
- CET 4.50%
- JANX N/A
- EPS Growth
- CET N/A
- JANX N/A
- EPS
- CET 7.40
- JANX N/A
- Revenue
- CET $27,062,484.00
- JANX $439,000.00
- Revenue This Year
- CET N/A
- JANX N/A
- Revenue Next Year
- CET N/A
- JANX $89.91
- P/E Ratio
- CET $6.90
- JANX N/A
- Revenue Growth
- CET 15.78
- JANX N/A
- 52 Week Low
- CET $40.24
- JANX $21.73
- 52 Week High
- CET $52.42
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- CET 50.97
- JANX 59.73
- Support Level
- CET $50.54
- JANX $27.40
- Resistance Level
- CET $51.87
- JANX $31.59
- Average True Range (ATR)
- CET 0.81
- JANX 1.84
- MACD
- CET -0.04
- JANX 0.21
- Stochastic Oscillator
- CET 50.14
- JANX 60.52
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.